Effect of different components of laser immunotherapy in treatment of metastatic tumors in rats.
Effect of different components of laser immunotherapy in treatment of metastatic tumors in rats.
复制标题
DOI：
--
复制
发表时间：
2002-08
期刊：
影响因子：
11.2
通讯作者：
Wei R. Chen;Hong Liu;J. Ritchey;K. Bartels;M. D. Lucroy;R. Nordquist
中科院分区：
文献类型：
--
作者：
Wei R. Chen;Hong Liu;J. Ritchey;K. Bartels;M. D. Lucroy;R. Nordquist
诱导长期肿瘤特异性免疫是转移性癌症的最终治愈。激光免疫治疗是一种新的治疗方法，其目的是针对肿瘤刺激宿主的免疫系统。它包括在肿瘤内给予激光吸收染料和免疫佐剂，然后进行非侵入性激光照射。以前的研究使用糖化壳聚糖（GC）作为免疫佐剂和吲哚菁绿色（ICG）作为激光吸收染料显示了治疗大鼠转移性乳腺肿瘤的积极作用。体内实验显示了有希望的结果，例如：（a）根除治疗的原发性肿瘤;（B）消退未治疗的转移;（c）诱导抗肿瘤免疫应答;和（d）对肿瘤再攻击的长期抗性。在这项研究中，大鼠转移性乳腺肿瘤和转移性前列腺肿瘤进行了治疗的三个组成部分的激光免疫疗法的各种组合。分析了用单独组分和组分的各种组合治疗后的大鼠存活率和原发性和转移性肿瘤的概况。在乳腺肿瘤的治疗中，所有没有免疫佐剂的实验组都显示出很少或没有积极的效果。GC单独使用或与其他成分联合使用对荷瘤大鼠的存活率有明显影响。然而，这三种成分的组合导致了最高的治愈率。三种不同浓度的GC，0.5%、1%和2%，也被用于治疗转移性乳腺肿瘤。结果表明，1%GC激光免疫治疗效果最好。在转移性前列腺肿瘤的治疗中，激光-ICG和激光-ICG-GC治疗均显著降低原发性肿瘤和肺转移瘤的生长。在我们的初步研究中，还观察到激光免疫治疗后携带前列腺肿瘤的大鼠的长期存活。这些结果揭示了免疫佐剂在激光免疫治疗中的重要作用。
Induction of a long-term tumor-specific immunity is the ultimate cure of metastatic cancers. Laser immunotherapy is a novel approach that aims at the tumor-directed stimulation of the immune system of the host. It involves an intratumor administration of a laser-absorbing dye and an immunoadjuvant, followed by noninvasive laser irradiation. Previous studies using glycated chitosan (GC) as immunoadjuvant and indocyanine green (ICG) as laser-absorbing dye have shown positive effects of the treatment on metastatic breast tumors in rats. In vivo experiments showed promising results such as: (a) eradication of treated primary tumors; (b) regression of untreated metastases; (c) induced antitumor immune response; and (d) long-term resistance to tumor rechallenge. In this study, rats bearing metastatic breast tumors and metastatic prostate tumors were treated with various combinations of the three components of laser immunotherapy. The rat survival rates and profiles of primary and metastatic tumors, after treatment by individual components and various combinations of the components, were analyzed. In the treatment of breast tumors, all of the experimental groups without immunoadjuvant showed little or no positive effect. The use of GC, either by itself or in combination with other components, had a noticeable impact on the survival rate of tumor-bearing rats. However, it was the combination of all of the three components that resulted in the highest cure rate. Three different concentrations of GC, 0.5, 1, and 2%, were also used to treat the metastatic breast tumors. The results showed that 1% GC was most effective in laser immunotherapy. In the treatment of metastatic prostate tumors, both the laser-ICG and laser-ICG-GC treatments significantly reduced the growth of primary tumors and lung metastases. Long-term survival of the rats bearing the prostate tumors was also observed after the laser immunotherapy treatment in our preliminary studies. These results revealed the important function of the immunoadjuvant in laser immunotherapy.